Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Risk-Based Quality Assessment Growing Among ANDA Chemistry Reviews

Executive Summary

The Office of Generic Drugs implemented risk-based quality assessment for some ANDA chemistry reviews in 2013 and found it helped speed up the process and enabled reviewers to better handle the submission volume.

You may also be interested in...



ANDA Avalanche: How Will FDA Deal With The 600 Received This Month?

Experts say one idea may be to borrow some new drug staff to help relieve the pressure; FDA says it will use all available resources.

FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues

FDA could help create several international coalitions to carry out its new globalization plan, which could allow for issue-specific groups focused on individual pharmaceutical sectors.

Postmarketing Trial For Horizon Thyroid Eye Drug Tepezza To Be Larger Than Expected

Horizon CEO says safety trial will be conducted in a larger patient population following discussions during the US FDA advisory committee meeting.

Topics

UsernamePublicRestriction

Register

PS056222

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel